Stock page
OrthoCellix Inc (OCLX)
OrthoCellix Inc is a biotechnology company focused on discovering, developing, and commercializing new regenerative cell therapies that improve health and offer hope for patients across the globe. Its initial product candidate is a Phase 3-ready regenerative cell therapy platform technology, NeoCart, which combines breakthroughs in bioengineering and cell processing to enhance the autologous cartilage repair process and is being developed for the repair of knee cartilage injuries in adults. NeoCart is a three-dimensional tissue-engineered disc of new cartilage that is manufactured by growing the patient's own chondrocytes, the cells responsible for maintaining cartilage health.
Quote snapshot
$0.00
Daily change: —
ExchangeNAS
Updated2026-05-09T04:31:47.116727Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|